Sullivan SD, Buxton M, Andersson LF, et al. J Allergy Clin Immunol. 2003;112:1229–1236

These investigators analyzed cost-effectiveness of a commonly prescribed inhaled corticosteroid from the perspectives of both direct and indirect costs.

Patients aged 5 to 66 years from 32 countries were enrolled in the Inhaled Steroid as Regular Therapy in Early Asthma (START) study. Patients were eligible if they were diagnosed with asthma within 2 years of randomization and lacked significant comorbidity.

START was a randomized, 3-year controlled trial of budesonide versus usual asthma therapy in early-onset asthma among 7165 subjects. Three age groups (5–10, 11–17, and ≥18 years) were studied separately and collectively. All patients were allowed to receive other asthma treatments including inhaled and oral corticosteroids, according to local practice. The cost-effectiveness evaluation of the START study was conducted primarily from the health care payer perspective (direct costs) and secondarily from the societal perspective (indirect costs)....

You do not currently have access to this content.